Head-to-head · WeighScore
Oak vs Tablet Health
The verdict
Oak takes it — 75.9/100 to 47.6/100.
Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Oak | Tablet Health |
|---|---|---|
| WeighScore | 75.9/100 | 47.6/100 |
| Grade | C | C |
| Scorecard rank | #42 | #495 |
| Semaglutide | From $119/mo | Not disclosed |
| Tirzepatide | From $185/mo | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #42 · C
Strengths
- Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
- One price across every dosage, so titrating up costs no more
- No membership or subscription fee, and free shipping
- All 50 states, offered in Spanish as well as English
Where it loses points
- Same-day approval with no video call means very little clinical contact before a prescription
- No published lab or monitoring programme
- Injection only, and no brand-name lane
- Sold as packages, so re-ordering is on you
Graded #495 · C
Strengths
- LegitScript Certified
- Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
- Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
- Mid-tier pricing starting $179–$299/mo across all four product variants
- No commitment — cancel anytime
Where it loses points
- States served not published — you must complete the intake quiz to learn eligibility
- No founder, CEO, medical director, or pharmacist-in-charge named anywhere
- No BBB profile found
- Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.